Advanced glycation end product level, diabetes, and accelerated cognitive aging

被引:114
作者
Yaffe, K. [1 ,2 ,3 ,5 ]
Lindquist, K. [4 ]
Schwartz, A. V. [3 ]
Vitartas, C. [1 ,5 ]
Vittinghoff, E. [3 ]
Satterfield, S. [6 ]
Simonsick, E. M. [7 ]
Launer, L. [8 ]
Rosano, C. [9 ]
Cauley, J. A. [9 ]
Harris, T. [8 ]
机构
[1] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA
[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA
[5] San Francisco VA Med Ctr, San Francisco, CA USA
[6] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA
[7] NIA, Clin Res Branch, Baltimore, MD 21224 USA
[8] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Baltimore, MD 21224 USA
[9] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA
关键词
ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PENTOSIDINE; ACCUMULATION; DEMENTIA; DECLINE; ELDERS; HEALTH; SERUM;
D O I
10.1212/WNL.0b013e3182315a56
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Several studies report that diabetes increases risk of cognitive impairment; some have hypothesized that advanced glycation end products (AGEs) underlie this association. AGEs are cross-linked products that result from reactions between glucose and proteins. Little is known about the association between peripheral AGE concentration and cognitive aging. Methods: We prospectively studied 920 elders without dementia, 495 with diabetes and 425 with normal glucose (mean age 74.0 years). Using mixed models, we examined baseline AGE concentration, measured with urine pentosidine and analyzed as tertile, and performance on the Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) at baseline and repeatedly over 9 years. Incident cognitive impairment (a decline of > 1.0 SD on each test) was analyzed with logistic regression. Results: Older adults with high pentosidine level had worse baseline DSST score (p = 0.05) but not different 3MS score (p = 0.32). On both tests, there was a more pronounced 9-year decline in those with high and mid pentosidine level compared to those in the lowest tertile (3MS 7.0, 5.4, and 2.5 point decline, p overall < 0.001; DSST 5.9, 7.4, and 4.5 point decline, p = 0.03). Incident cognitive impairment was higher in those with high or mid pentosidine level than those in the lowest tertile (3MS: 24% vs 17%, odds ratio = 1.55; 95% confidence interval 1.07-2.26; DSST: 31% vs 22%, odds ratio = 1.62; 95% confidence interval 1.13-2.33). There was no interaction between pentosidine level, diabetes status, and cognitive decline. Multivariate adjustment for age, sex, race, education, hypertension, cardiovascular disease, estimated glomerular filtration rate, and diabetes diminished results somewhat but overall patterns remained similar. Conclusion: High peripheral AGE level is associated with greater cognitive decline in older adults with and without diabetes. Neurology (R) 2011;77:1351-1356
引用
收藏
页码:1351 / 1356
页数:6
相关论文
共 31 条
  • [1] Pentosidine and Nε-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia
    Bär, KJ
    Franke, S
    Wenda, B
    Müller, S
    Kientsch-Engel, R
    Stein, G
    Sauer, H
    [J]. NEUROBIOLOGY OF AGING, 2003, 24 (02) : 333 - 338
  • [2] Oxidative stress in Alzheimer's disease hippocampus: A topographical study
    Cruz-Sanchez, F. F.
    Girones, X.
    Ortega, A.
    Alameda, F.
    Lafuente, J. V.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 299 (1-2) : 163 - 167
  • [3] Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies
    Cukierman, T
    Gerstein, HC
    Williamson, JD
    [J]. DIABETOLOGIA, 2005, 48 (12) : 2460 - 2469
  • [4] RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
    Deane, R
    Yan, SD
    Submamaryan, RK
    LaRue, B
    Jovanovic, S
    Hogg, E
    Welch, D
    Manness, L
    Lin, C
    Yu, J
    Zhu, H
    Ghiso, J
    Frangione, B
    Stern, A
    Schmidt, AM
    Armstrong, DL
    Arnold, B
    Liliensiek, B
    Nawroth, P
    Hofman, F
    Kindy, M
    Stern, D
    Zlokovic, B
    [J]. NATURE MEDICINE, 2003, 9 (07) : 907 - 913
  • [5] Dickson DW, 1996, NEUROBIOL AGING, V17, P733
  • [6] Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons
    Horie, K
    Miyata, T
    Yasuda, T
    Takeda, A
    Yasuda, Y
    Maeda, K
    Sobue, G
    Kurokawa, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) : 327 - 332
  • [7] Diabetes and advanced glycoxidation end products
    Huebschmann, Amy G.
    Regensteiner, Judith G.
    Vlassara, Helen
    Reusch, Jane E. B.
    [J]. DIABETES CARE, 2006, 29 (06) : 1420 - 1432
  • [8] Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?
    Krautwald, Martina
    Muench, Gerald
    [J]. EXPERIMENTAL GERONTOLOGY, 2010, 45 (10) : 744 - 751
  • [9] A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
    Levey, AS
    Bosch, JP
    Lewis, JB
    Greene, T
    Rogers, N
    Roth, D
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) : 461 - +
  • [10] Livak Kenneth J, 2003, Methods Mol Biol, V212, P129